Product code

• J9183 — Gemcitabine intravesical system, 225 mg.
• Each 225-mg intravesical system represents 1 unit of J9183.

NDC reporting

• 10-digit NDC: 57894-225-01
• 11-digit NDC: 57894-0225-01
• NDC unit of measure: UN
• NDC units: 1
• Example professional claim format: N457894022501 UN1

Procedure codes

• 51720 — Bladder instillation of anticarcinogenic agent (including retention time).
• 52310 — Cystourethroscopy, with removal of foreign body, calculus, or ureteral stent from urethra or bladder; simple. Use only when supported by the removal service documented.

Common diagnosis codes that may be relevant when supported by the record include:

• C67.0 — Malignant neoplasm of trigone of bladder
• C67.1 — Malignant neoplasm of dome of bladder
• C67.2 — Malignant neoplasm of lateral wall of bladder
• C67.3 — Malignant neoplasm of anterior wall of bladder
• C67.4 — Malignant neoplasm of posterior wall of bladder
• C67.5 — Malignant neoplasm of bladder neck
• C67.6 — Malignant neoplasm of ureteric orifice
• C67.8 — Malignant neoplasm of overlapping sites of bladder
• C67.9 — Malignant neoplasm of bladder, unspecified
• D09.0 — Carcinoma in situ of bladder
• Z85.51 — Personal history of malignant neoplasm of bladder

Practical point: Code to the highest specificity supported by the treating record and align diagnosis reporting with the approved indication and payer medical-necessity policy.

Documentation should support both the product and the professional work performed.

• Diagnosis: bladder cancer site, CIS status, BCG-unresponsive status, relevant prior therapy, and clinical rationale for treatment.
• Product: INLEXZO™ name, dose/system, NDC when required by the payer, lot/serial information per practice policy, and whether the product was obtained through buy-and-bill or specialty pharmacy.
• Insertion: intravesical administration/insertion details, catheter/stylet use, date of insertion, and tolerance/complications.
• Removal: removal date, cystoscopy/removal details when applicable, and whether a new system was inserted on the same date.
• Medical necessity: treatment rationale, prior therapy history, current disease status, and payer-required prior authorization or exception documentation.
• Claim support: prior authorization number if required, NDC quantity/unit, J-code units, and any payer-specific attachments.

Modifier and claim considerations

• JZ modifier: Medicare requires reporting JZ on separately payable Part B single-dose container drugs when no amount is discarded. Confirm payer instructions for INLEXZO™ claims.
• POS 11: physician office claims generally use place of service 11 when the service is furnished in the office.
• Prior authorization: many payers may require prior authorization or medical exception review; verify before treatment.

Common physician-side pitfalls

• NDC mismatch: payer requires 11-digit NDC but claim reports a 10-digit format or omits the N4 qualifier.
• Unit mismatch: J9183 unit and NDC unit logic do not align with the system actually used.
• Procedure ambiguity: insertion/removal details are not clear enough to support the procedure code billed.
• Authorization gap: drug authorization obtained but procedure/site-of-care authorization not confirmed, or vice versa.
• Buy-and-bill vs specialty pharmacy confusion: acquisition pathway not aligned with payer benefit determination.

Product and revenue coding

• J9183 — Gemcitabine intravesical system, 225 mg.
• 11-digit NDC: 57894-0225-01.
• Revenue code 0636 — Pharmacy, drugs requiring detailed coding. Typically relevant for hospital outpatient drug reporting.

Procedure coding

• 51720 — Bladder instillation of anticarcinogenic agent (including retention time).
• 52310 — Cystourethroscopy with simple removal from urethra or bladder, when supported by documentation.
• Revenue code 0360 — Operating room services, general, when applicable to the facility service line and payer instructions.

Claim forms

• HOPD: generally reported on CMS-1450 / UB-04 or electronic 837I.
• ASC: payer and contracting rules may drive CMS-1500/837P versus institutional reporting requirements. Confirm payer instructions before go-live.

Facility diagnosis reporting should match the reason for the encounter and the treating record. Common codes include:

• C67.0-C67.9 — Malignant neoplasm of bladder by anatomic site
• D09.0 — Carcinoma in situ of bladder
• Z85.51 — Personal history of malignant neoplasm of bladder

Practical point: In outpatient facility reporting, use the first-listed diagnosis that best explains the encounter and code all additional relevant conditions supported by the documentation.

Facility reimbursement depends on clean alignment among the physician note, nursing record, supply log, pharmacy record, chargemaster, and claim.

• Product capture: INLEXZO™ system, NDC, quantity, acquisition pathway, pharmacy/supply documentation, and charge capture.
• Procedure capture: insertion/removal services, cystoscopy if performed, same-day removal/new insertion if applicable, and operating/procedure room resources.
• Authorization support: payer authorization number, coverage determination, benefit category, and exception/appeal documentation if needed.
• Revenue integrity: line-item charges should match documented drug, procedure, and supply use.
• Record alignment: physician order, operative/procedure note, medication administration record, nursing notes, and claim lines should tell the same story.

Acquisition and site-of-care issues

• Dual procurement pathways: determine whether payer coverage supports buy-and-bill or specialty pharmacy before ordering.
• Benefits investigation: use J&J withMe or payer-specific workflows to verify coverage, prior authorization, patient cost share, and acquisition pathway.
• Appeals readiness: maintain denial reason, original claim, prior authorization record, medical necessity support, and product information for appeal submissions.

Common facility-side pitfalls

• Missing revenue code: HOPD drug line lacks detailed coding support when the payer expects it.
• Product/procedure split: product is documented, but the procedure service line is incomplete or not supported.
• Specialty pharmacy confusion: facility bills for product it did not acquire or payer expects alternate billing pathway.
• NDC formatting issues: electronic claim rejects because NDC format, qualifier, unit of measure, or quantity is not payer compliant.